Skip to main content
ADMA
NASDAQ Life Sciences

律师事务所调查ADMA Biologics涉嫌证券欺诈后29%的股票暴跌

feedReported by Access Newswire
Sentiment info
Negative
Importance info
7
Price
$9.221
Mkt Cap
$2.203B
52W Low
$7.21
52W High
$25.67
Market data snapshot near publication time

summarizeSummary

一家证券法律事务所Bleichmar Fonti & Auld LLP宣布对ADMA Biologics进行调查，原因是其可能违反了联邦证券法。这次调查是在2026年3月23日至2026年3月25日之间，股票下跌了29%之后进行的，在此期间，Culper Research于2026年3月24日发布了一份报告，指控ADMA Biologics存在渠道填充和2025年收入增长的虚假陈述。虽然空头报告和最初的股票反应之前已经被公司在最近的新闻和8-K文件中披露，但律师事务所正式启动法律调查为ADMA Biologics带来了新的法律和财务风险。投资者应该关注这次调查和任何潜在的集体诉讼的发展。

在该公告发布时，ADMA的交易价格为$9.22，交易所为NASDAQ，所属行业为Life Sciences，市值约为$22亿。 52周交易区间为$7.21至$25.67。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Access Newswire。

show_chartPrice Chart

Share this article

Copied!

feed ADMA - Latest Insights

ADMA
Apr 15, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ADMA Biologics Details Strong 2025 Performance, Executive Compensation, and Pipeline Progress in Definitive Proxy
Sentiment: Positive
View Wiseek Article
ADMA
Mar 28, 2026, 6:18 AM EDT
Source: Access Newswire
Importance Score:
7
Law Firm Investigates ADMA Biologics for Securities Fraud After 29% Stock Plunge
Sentiment: Negative
View Wiseek Article
ADMA
Mar 27, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Issues Detailed Rebuttal to Short-Seller Allegations with Supporting Data
Sentiment: Positive
View Wiseek Article
ADMA
Mar 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
ADMA Biologics Rejects Short-Seller Claims, Citing Strong ASCENIV Demand and Industry-Standard Inventory
Sentiment: Neutral
View Wiseek Article
ADMA
Mar 25, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Misleading Short-Seller Report Allegations Rebutted by ADMA Biologics
Sentiment: Negative
View Wiseek Article
ADMA
Mar 02, 2026, 7:13 AM EST
Source: Unknown
Importance Score:
8
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of ~$200M 2026 Buyback Plan
Sentiment: Positive
View Wiseek Article
ADMA
Mar 02, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
ADMA Biologics Launches $125M Accelerated Share Repurchase, Part of $200M 2026 Capital Return Plan
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 5:16 PM EST
Filing Type: 10-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financials, Driven by ASCENIV Growth and Strategic Initiatives
Sentiment: Positive
View Wiseek Article
ADMA
Feb 25, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Reports Record 2025 Financial Results, Strong 2026-2029 Guidance, and Smooth CFO Transition
Sentiment: Positive
View Wiseek Article
ADMA
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8
ADMA Biologics Raises 2026 Guidance, Projects Strong Long-Term Growth to $1.1B Revenue by 2029
Sentiment: Positive
View Wiseek Article